(Q38804116)

6 September 2017

title

Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma (English)

1 reference

6 September 2017

0 references

1 reference

Kulthida Vaeteewoottacharn

1

1 reference

6 September 2017

Ryusho Kariya

2

1 reference

6 September 2017

Paweena Dana

3

1 reference

6 September 2017

Sawako Fujikawa

4

1 reference

6 September 2017

Kouki Matsuda

5

1 reference

6 September 2017

Koichi Ohkuma

6

1 reference

6 September 2017

Eriko Kudo

7

1 reference

6 September 2017

Ratthaphol Kraiklang

8

1 reference

6 September 2017

Chaisiri Wongkham

9

1 reference

6 September 2017

Sopit Wongkham

10

1 reference

6 September 2017

Seiji Okada

11

1 reference

6 September 2017

publication date

13 January 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

37

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

9023-9035

1 reference

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Targeted therapy for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Gene expression and hypoxia in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

COMMD1/Murr1 reinforces HIV-1 latent infection through IκB-α stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Cholangiocarcinoma: lessons from Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-016-4785-8

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

12 December 2020

A novel EGFP-expressing nude mice with complete loss of lymphocytes and NK cells to study tumor-host interactions.

1 reference

12 December 2020

Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development

1 reference

12 December 2020

Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan

1 reference

12 December 2020

Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma

1 reference

12 December 2020

State of serum markers for detection of cholangiocarcinoma

1 reference

12 December 2020

High expression of HIF-1α, BNIP3 and PI3KC3: hypoxia-induced autophagy predicts cholangiocarcinoma survival and metastasis

1 reference

12 December 2020

Establishment of nude mice with complete loss of lymphocytes and NK cells and application for in vivo bio-imaging.

1 reference

12 December 2020

Hypoxia enhances aggressiveness of cholangiocarcinoma cells.

1 reference

12 December 2020

10.1007/S13277-016-4785-8

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1014229975

0 references

1 reference